Active	Status	Sponsor type	Region	Phase	Filter
1 Active 39 Inactive 40 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Raylumis (tanezumab) / Eli Lilly, Pfizer
NCT04163419: Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis	Active, not recruiting	2	9	US	Tanezumab, PF-04383119, Placebo	Massachusetts General Hospital, Pfizer	Schwannomatosis, Pain	09/22	09/24